This biotech's advanced breast cancer drug got the green light from the FDA.
News & Analysis: Immunomedics
IMMU earnings call for the period ending March 31, 2020.
The company won an early FDA approval yesterday for its drug to treat advanced breast cancer.
Trodelvy is the first treatment approved specifically for triple-negative breast cancer.
Investors piled into cancer stocks. Here's why.
Exelixis and Immunomedics could be two of the biggest winners within the high-growth cancer space.
Sacituzumab govitecan has proven effective against triple-negative breast cancer.
A Wall Street downgrade raises concerns its lead pipeline candidate might fail to secure an FDA OK in June.
Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.
IMMU earnings call for the period ending December 31, 2019.